Esketamine tops quetiapine for treatment-resistant depression in head-to-head trial
Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.
Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in patients with depressive episodes that didn’t respond to two or more consecutive treatments, according to a study published Wednesday in the New England Journal of Medicine.
Research dating back to the early 2000s has shown that ketamine and esketamine — which is derived from ketamine — are effective in cases of so-called treatment-resistant depression, and the nasal spray version of the drug was specifically approved for this indication in 2019.
What's Your Reaction?
